Gatifloxacin is a quinolone antibiotic also known as Tequin. While Tequin, which is marketed by Bristol- Myers Squibb is no longer sold as a tablet in the U.S., it is still sold in other countries in tablet form, like China. In the United States gatifloxacin is sold as an opthalmic solution, also known as Zymar, and marketed by Allergan. LGM Pharma offers the gatifloxacin CAS# 112811-59-3 API for research purposes, as well as the gatifloxacin TEVA API for compounding purposes. With a patent expiring on December 5, 2015, the door is open for research and development of gatifloxacin for the oral or opthalmic antibiotic products.
As a quinolone antibiotic gatifloxacin is efficient for treating bacterial infections of the lungs, sinuses, skin, and urinary tract. It is also used to treat certain sexually transmitted diseases. Patients with a personal or family history of “Long QT syndrome”, heart diseases, low potassium levels, liver disease or epilepsy should not take gatifloxacin. Side effects may include diarrhea, headache, nausea, and dizziness. Available in either 200 or 400 milligram tablets, gatifloxacin should be taken with a full glass of water. Gatifloxacin is an effectual antibiotic of the third-generation fluoroquinolone family, and inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in under the proprietary name Tequin in 1999, and it was originally intended for the treatment of respiratory tract infections. Quinolones are unique in that they can act as antibacterial drugs which inhibit DNA replication, and as a whole they are commonly used as treatment for a wide variety of infections. When comparing first and second generation quinolones, such as cinoxacin and ofloxacin, third-generation quinolones like moxifloxacin and gatifloxacin offer a broader range of activity against both gram-negative and gram-positive activity. Gatifloxacin is particularly effective as a treatment for acute exacerbations of chronic bronchitis, community-acquired pneumonia, and Streptococcus pneumoniae.
|Photo courtesy of: medicinenet.com|
Gatifloxacin ophthalmic solution is efficacious for treating bacterial conjunctivitis, also known as “pinkeye”. This infection of the membrane that covers the outside of the eyeballs and also the inside of the eyelids can threaten the eyesight of affected patients. The solution is usually prescribed as one drop in each affected eye, every 2 hours while awake for 2 days. The following 5 days the patient should administer the drops 4 times daily. Side effects for gatifloxacin eye drops include the possibility of red and irritated eyes, itching, teary eyes, blurred vision, eye discharge, swelling of the eyelids, broken blood vessels in the eye and headache. In Cataract and Refractive Surgery Today, Gatifloxacin opthalmic solution is praised as it offers a wide spectrum for the treatment of gram-positive organisms and exhibits concentration-dependent killing of harmful bacteria. Gatifloxacin is also deemed superior to other antibiotic eye-drops as it penetrates extremely well into the ocular tissues. With the apparent risk of resistant strains of bacteria, as well as an increased resistance in ocular isolates, continued research and development of Gatifloxacin is both advantageous and prudent.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.